NEW YORK (GenomeWeb News) – Presenting at an investors meeting in London this week, Roche said this week that is has more than 200 companion diagnostic projects ongoing across its pharma and diagnostics units. "More than 60 percent of our pharmaceutical pipeline projects are couples with the development of companion diagnostics in order to make treatments more effective," Roche CEO Severin Schwan said.

The firm also noted that approximately 50 percent of its R&D budget is allocated to oncology drugs and diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.